Group 1 - The core viewpoint of the articles highlights the financial performance and market position of HeFu China, particularly its high PE ratio compared to industry averages [1][2] - HeFu China's closing price on August 11 was 7.37 yuan, with a 1.52% increase, resulting in a rolling PE ratio of 203.28, which is the lowest in 100 days, and a total market capitalization of 2.934 billion yuan [1] - The average PE ratio for the pharmaceutical distribution industry is 44.67, with a median of 30.06, positioning HeFu China at 26th place within the industry [1][2] Group 2 - As of March 31, 2025, HeFu China had 33,527 shareholders, a decrease of 3,450 from the previous count, with an average holding value of 352,800 yuan and an average shareholding of 27,600 shares per shareholder [1] - The main business of HeFu China involves international trade and after-sales services related to in vitro diagnostic medical devices and consumables, as well as consulting services for hospital information management systems [1] - The latest quarterly report for Q1 2025 shows HeFu China achieved a revenue of 176 million yuan, a year-on-year decrease of 26.35%, with a net loss of approximately 6 million yuan, reflecting a year-on-year decline of 184.13%, and a gross profit margin of 16.71% [1]

证券代码：603122 证券简称：合富中国 公告编号：临 2025-033 合富（中国）医疗科技股份有限公司 《证券日报》和上海证券交易所网站（http://www.sse.com.cn）上披露本公司 营业收入。本简报为初步核算数据，未经会计师事务所审计或审阅，最终数据 以公司定期报告为准，敬请投资者注意投资风险。 公司 2025 年 1-7 月合并营业收入人民币 42,512.74 万元，较去年同期下降 特此公告。 合富（中国）医疗科技股份有限公司董事会 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 合富（中国）医疗科技股份有限公司（以下简称"公司"）之间接控股股东 合富医疗控股股份有限公司（以下简称"合富控股"）为台湾地区证券柜台买 卖中心上柜公司，合富控股需按照台湾证券交易所相关规定，每月披露营业收 入数据。为使 A 股投资者能够及时了解公司的经营情况，本公司亦同步在上海 证券交易所指定的信息披露媒体《上海证券报》、《中国证券报》、《证券时报》、 ...

合富（中国）医疗科技股份有限公司 证券代码：603122 证券简称：合富中国 公告编号：临 2025-033 公司 2025 年 1-7 月合并营业收入人民币 42,512.74 万元，较去年同期下降 22.66%，2025 年 1-6 月合并营业收入较去年同期下降 23.53%，下降幅度收窄 0.87%，营收情况持续改善。 特此公告。 合富（中国）医疗科技股份有限公司董事会 2025 年 8 月 12 日 1 2025 年 1-7 月累计营业收入简报 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 合富（中国）医疗科技股份有限公司（以下简称"公司"）之间接控股股东 合富医疗控股股份有限公司（以下简称"合富控股"）为台湾地区证券柜台买 卖中心上柜公司，合富控股需按照台湾证券交易所相关规定，每月披露营业收 入数据。为使 A 股投资者能够及时了解公司的经营情况，本公司亦同步在上海 证券交易所指定的信息披露媒体《上海证券报》、《中国证券报》、《证券时报》、 《证券日报》和上海证券交易所网站（http://www.sse.com.cn ...

Group 1 - The core point of the article is that 合富中国 (603122.SH) reported a decline in consolidated revenue for the first seven months of 2025, amounting to RMB 425 million, which represents a decrease of 22.66% compared to the same period last year [1] - For the first six months of 2025, the consolidated revenue also showed a decline of 23.53% year-on-year, although the rate of decline has narrowed by 0.87%, indicating a continuous improvement in revenue situation [1]

Group 1 - The core point of the article is that HeFu China (603122) reported a decline in consolidated revenue for the first seven months of 2025, amounting to 425 million yuan, which represents a decrease of 22.66% compared to the same period last year [1] - For the first six months of 2025, the consolidated revenue also showed a decline of 23.53% year-on-year, although the rate of decline has narrowed by 0.87%, indicating a continuous improvement in revenue situation [1]

Core Viewpoint - The company reported a decline in consolidated revenue for the first seven months of 2025, indicating ongoing challenges but a slight improvement in the rate of revenue decline compared to previous months [1] Revenue Performance - For the period of January to July 2025, the company's consolidated revenue was RMB 425.1274 million, representing a decrease of 22.66% compared to the same period last year [1] - In the first six months of 2025, the consolidated revenue also showed a decline of 23.53% year-on-year, but the rate of decline improved by 0.87% compared to the previous period [1]

[Current Period Performance Forecast](index=1&type=section&id=%E4%B8%80%E3%80%81%E6%9C%AC%E6%9C%9F%E4%B8%9A%E7%BB%A9%E9%A2%84%E5%91%8A%E6%83%85%E5%86%B5) The company anticipates a loss for the first half of 2025, with net profit attributable to owners of the parent company projected to be between -9.0 million RMB and -6.3 million RMB Estimated Performance Indicators | Performance Indicators | Estimated Amount (RMB) | | :--- | :--- | | Net Profit Attributable to Owners of the Parent Company | -9.0 million to -6.3 million | | Net Profit Attributable to Owners of the Parent Company After Deducting Non-Recurring Gains and Losses | -8.72 million to -6.02 million | [Prior Period Operating Performance and Financial Position](index=1&type=section&id=%E4%BA%8C%E3%80%81%E4%B8%8A%E5%B9%B4%E5%90%8C%E6%9C%9F%E7%BB%8F%E8%90%A5%E4%B8%9A%E7%BB%A9%E5%92%8C%E8%B4%A2%E5%8A%A1%E7%8A%B6%E5%86%B5) Contrary to the current period's projected loss, the company achieved profitability in the prior period (first half of 2024), with net profit attributable to owners of the parent company at 22.5219 million RMB Prior Period Performance Indicators | Performance Indicators | Amount (RMB) | | :--- | :--- | | Total Profit | 31.2322 million | | Net Profit Attributable to Owners of the Parent Company | 22.5219 million | | Net Profit Attributable to Owners of the Parent Company After Deducting Non-Recurring Gains and Losses | 20.7641 million | | Earnings Per Share | 0.06 RMB/share | [Primary Reasons for Current Period's Projected Loss](index=2&type=section&id=%E4%B8%89%E3%80%81%E6%9C%AC%E6%9C%9F%E4%B8%9A%E7%BB%A9%E9%A2%84%E4%BA%8F%E7%9A%84%E4%B8%BB%E8%A6%81%E5%8E%9F%E5%9B%A0) The current period's projected loss is primarily due to declining sales revenue and gross profit, increased R&D and market investment, exchange losses, and a slower reduction in expenses - Sales revenue and gross profit simultaneously declined due to the domestic macroeconomic environment and policies such as centralized procurement price reductions, leading to lower hospital client purchase prices and reduced order volumes[8](index=8&type=chunk) - To adapt to market changes, the company adjusted its business layout, continuously investing resources in the iterative R&D, production, and market development of its proprietary "ACME" product[8](index=8&type=chunk) - The appreciation of the New Taiwan Dollar resulted in exchange losses for the company, negatively impacting net profit[8](index=8&type=chunk) - Despite implementing expense controls, the short-term decrease in administrative and selling expenses was less than the reduction in revenue, contributing to the performance decline[8](index=8&type=chunk) [Risk Warning and Other Disclosures](index=2&type=section&id=%E5%9B%9B%E3%80%81%E9%A3%8E%E9%99%A9%E6%8F%90%E7%A4%BA) The company explicitly states that this performance forecast data is a preliminary calculation and has not been audited, with the final accurate financial data to be released in the official 2025 semi-annual report - This performance forecast has not been audited by a certified public accountant, and the final accurate data will be based on the company's officially disclosed 2025 semi-annual report[9](index=9&type=chunk)[10](index=10&type=chunk)

合富中国（603122）公告，预计2025年半年度归属于母公司所有者的净利润为-900万元到-630万元，与 上年同期相比，将出现亏损。预计2025年半年度实现归属于母公司所有者的扣除非经常性损益后的净利 润为-872万元到-602万元。 ...

合富（中国）医疗科技股份有限公司董事会 2025 年 7 月 11 日 1 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 合富（中国）医疗科技股份有限公司（以下简称"公司"）之间接控股股东 合富医疗控股股份有限公司（以下简称"合富控股"）为台湾地区证券柜台买 卖中心上柜公司，合富控股需按照台湾证券交易所相关规定，每月披露营业收 入数据。为使 A 股投资者能够及时了解公司的经营情况，本公司亦同步在上海 证券交易所指定的信息披露媒体《上海证券报》、《中国证券报》、《证券时报》、 《证券日报》和上海证券交易所网站（http://www.sse.com.cn）上披露本公司 营业收入。本简报为初步核算数据，未经会计师事务所审计或审阅，最终数据 以公司定期报告为准，敬请投资者注意投资风险。 公司 2025 年 1-6 月合并营业收入人民币 36,765.82 万元，较去年同期下降 23.53%，2025 年 1-5 月合并营业收入较去年同期下降 24.15%，下降幅度收窄 0.62%，营收情况持续改善。 特此公告。 证券代码：60312 ...

Core Viewpoint - 合富中国 reported a consolidated revenue of 368 million yuan for the first half of 2025, representing a year-on-year decline of 23.53% [1] Revenue Performance - The revenue for the first five months of 2025 showed a year-on-year decline of 24.15%, indicating a slight improvement in the revenue trend as the decline narrowed by 0.62% [1]